A trial looking at the V212 vaccine to prevent shingles in people having chemotherapy

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Acute leukaemia
Blood cancers
Chronic leukaemia
High grade lymphoma
Hodgkin lymphoma
Low grade lymphoma
Non-Hodgkin lymphoma




Phase 3

This trial is looking at a new vaccine called V212 to prevent shingles in people who are having chemotherapy for a solid tumour, leukaemia, lymphoma or myeloma.  

This trial is recruiting from different countries around the world but in the UK it is only recruiting people who have leukaemia Open a glossary item, lymphoma Open a glossary item or myeloma Open a glossary item.

Doctors often use chemotherapy to treat people with cancer. A side effect of chemotherapy is a drop in blood cells. The white blood cells are a part of the body’s immune system, which fights infections. A drop in white blood cells can increase your risk of getting an infection.

Shingles Open a glossary item is a virus that affects the nerves. It can travel along the nerve to the skin, causing a painful rash. Because of their low levels of white blood cells, people having chemotherapy are at a greater risk of getting shingles. The V212 vaccine may help these people.   

The aims of this trial are to find out

  • How well the V212 vaccine is at preventing shingles in people who are having chemotherapy
  • How safe the vaccine is for these people

Who can enter

You may be able to enter this trial if you have any cancer. But for people in the UK you must have leukaemia, lymphoma or myeloma.

You must also

  • Be having chemotherapy – you may be able to take part if you are not having chemotherapy as long as you are 50 years or older and have leukaemia, lymphoma or myeloma
  • Have had chickenpox  
  • Be willing to use reliable contraception for 2 weeks before starting treatment, during treatment and for 6 months afterwards if there is any chance you or your partner could become pregnant
  • Be at least 18 years old

You cannot enter this trial if you

  • Have a solid tumour and have had a transfusion of blood, red blood cells, or platelets in the last 3 months or may need a transfusion when having the vaccines or within a month afterwards
  • Have had shingles in the last year
  • Have had a vaccination for chickenpox or shingles
  • Are taking medicine to prevent cold sores or cytomegalovirus (CMV) – you may be able to join if you took this for less than a month
  • Had a live virus vaccine within a month of starting treatment or are due to have a live virus vaccine during treatment and up to a month afterwards
  • Are due to have an inactivated vaccine (containing dead virus or bacteria) a week before to a week after each trial treatment
  • Are allergic to the vaccine used in this trial or to a drug called neomycin – you may be able to take part if your reaction to neomycin was only a skin rash
  • Are pregnant or breastfeeding

Trial design

This is an international phase 3 trial. It will recruit 5,246 people from different countries around the world. It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.

Half the people will have the V212 injection. The other half will have a dummy drug (placebo).

trial diagram

You have a total of 4 injections each about a month apart.  

After each injection you take home a vaccination report card to fill in. For the first 5 days you record on the card any reaction at the site of injection, for example any redness, swelling or pain. For 28 days after your injection you record

  • Your temperature
  • Any side effects
  • Any medications you take
  • Any other vaccinations you have

You hand in your completed card at the next visit. You take a new card home to fill in after each injection.  

After you have had your last injection you will also need to phone an automated system. You will answer questions using your telephone keypad. This is to check if you have any signs of shingles. If your answers show that you may have signs of shingles your doctor or nurse will phone you. They may ask you to come in to see them.  

You continue to make these phone calls every month for a year after your last treatment.

If you prefer, you may be able to answer the questions on line using the Internet. You can talk about this with your research nurse.  

Hospital visits

You see the doctor to have a physical examination and blood tests before having your 1st injection. You then see your doctor monthly for 3 months to have blood tests and your next injections.

About a month after your last injection you see the doctor for blood tests.

Your doctor or nurse will phone you every 3 months for up to 5 years, to see how you are.

If you get a skin rash, or have symptoms of shingles, you must see a doctor as soon as possible, preferably within 1 to 3 days. They will do a physical examination and take a blood sample. If you have a skin rash, they will also ask your permission to take a skin sample.

They will see you every 3 to 5 days until no new areas of rash appear or your symptoms start to improve. After this they will see you every month for 6 months. You will also fill in a questionnaire. It will ask you about any pain you have had and how you have been feeling. This is called a quality of life study.

Side effects

The V212 vaccine is a new drug and there may be side effects that we don’t know about yet. Possible side effects include

  • A reaction at the injection site, such as swelling, pain, itching, bruising, warmth, hardening of the area around the site, discolouration, rash and a bump on the skin
  • Headache
  • Rash that looks like chickenpox
  • Itching
  • Fever
  • Muscle aches
  • Joint pain
  • Feeling or being sick
  • Numbness, tingling or burning feeling of the skin or pain in the hands or feet due to nerve damage

Your doctor will talk to you about the possible side effects of the V212 vaccine before you agree to take part in this trial.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Peniket

Supported by

Merck, Sharp & Dohme

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10662

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

Currently rated: 3 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think